SG Americas Securities LLC Has $267,000 Stock Position in Enfusion, Inc. (NYSE:ENFN)

SG Americas Securities LLC decreased its holdings in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 72.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,929 shares of the company's stock after selling 68,103 shares during the period. SG Americas Securities LLC's holdings in Enfusion were worth $267,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in shares of Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company's stock valued at $9,770,000 after purchasing an additional 70,367 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Enfusion by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock valued at $9,265,000 after purchasing an additional 61,032 shares in the last quarter. State Street Corp boosted its position in shares of Enfusion by 2.3% during the 3rd quarter. State Street Corp now owns 952,895 shares of the company's stock valued at $9,043,000 after purchasing an additional 21,729 shares in the last quarter. Impax Asset Management Group plc boosted its position in shares of Enfusion by 25.4% during the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company's stock valued at $6,424,000 after purchasing an additional 136,948 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Enfusion by 57.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company's stock valued at $4,466,000 after purchasing an additional 191,436 shares in the last quarter. Institutional investors own 81.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ENFN. Stifel Nicolaus raised their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. William Blair reiterated a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. Finally, Piper Sandler raised their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a report on Monday, December 23rd. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $10.50.

Enfusion Stock Performance

Shares of NYSE ENFN traded down $0.06 during mid-day trading on Friday, reaching $11.17. The company had a trading volume of 1,184,680 shares, compared to its average volume of 1,352,900. The stock has a fifty day moving average of $10.66 and a two-hundred day moving average of $9.52. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 279.19, a PEG ratio of 1.83 and a beta of 0.96. Enfusion, Inc. has a 12-month low of $7.83 and a 12-month high of $11.38.

Insider Transactions at Enfusion

In related news, CEO Oleg Movchan sold 2,771 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the transaction, the chief executive officer now owns 526,702 shares of the company's stock, valued at approximately $5,335,491.26. This trade represents a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Neal Pawar sold 21,801 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the transaction, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 57,367 shares of company stock valued at $591,335 over the last three months. 36.44% of the stock is owned by corporate insiders.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.